Rapport Therapeutics (RAPP) Director Silva Buys $100K of Stock

Director Paul M Silva bought shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP) on October 22, 2026, according to a Form 4 filing with the Securities and Exchange Commission.

RAPP Rapport Therapeutics, Inc.

$25.06 ▼ -10.85% year to date

1M 3M YTD

Daily close · Oct 21, 2026

Inside Paul M Silva's RAPP Trade

In the transaction, Silva picked up shares worth a total value of $99,636.00 at a price of $27.07 per share. Following the purchase, Silva held 3,680 shares of the clinical-stage biopharmaceutical company.

Other Institutional Activity in Rapport Therapeutics

Institutional investors adjusted their positions ahead of the filing period. Trv Gp V, LLC reduced its holdings by 854,814 shares, ending with 6,280,525 shares worth about $166,622,332.00. Arch Venture Management, Llc kept its stake steady at 3,728,738 shares valued at about $98,923,421.00. Capital International Investors trimmed its position by 175,962 shares to hold 2,921,958 shares worth approximately $77,519,547.00. Cormorant Asset Management, LP lowered its holdings by 299,881 shares, finishing with 2,657,521 shares valued at around $70,504,033.00. Sofinnova Investments, Inc. maintained its position at 1,904,408 shares worth about $50,523,945.00.

Rapport Therapeutics, Inc. Stock Up 5.9%

Rapport Therapeutics shares closed at $26.53 on October 22, 2026. The stock recently traded around $26.53, placing it below its 50-day moving average and its 200-day moving average.

Recent Earnings

The company reported trailing twelve-month revenue of $20.0 million and an EPS of -$3.03. Its net margin stood at 0.0% with a return on equity of -40.0%.

Insider Buying and Selling at Rapport Therapeutics, Inc.

Insider activity preceded the trade. Chief Operating Officer Cheryl Gault sold 10,000 shares on September 30, 2026, for a value of about $331,856.00. Chief Executive Officer Abraham N Ceesay sold 4,522 shares on October 7, 2026, valued at $143,273.00. Chief Financial Officer Troy A. Ignelzi bought 5,500 shares on October 21, 2026, for a total value of $143,550.00.

Analysts Set New Price Targets

Analyst firms continue to review the stock. HC Wainwright & Co. reiterated a buy rating with a $66.00 target on October 20, 2026. BTIG maintained a buy rating while lifting its target to $89.00 on October 20, 2026. Jones Trading maintained a buy rating on October 21, 2026, with a target of $82.00. Wells Fargo maintained an overweight rating with a $50.00 target on October 21, 2026. Guggenheim maintained a buy rating with a $70.00 target on October 21, 2026. The stock carries a consensus strong buy rating and a mean price target of $69.46 across 15 analyst opinions.

About Rapport Therapeutics

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. The firm focuses on discovering and developing small molecule medicines for patients dealing with central nervous system disorders.

Bottom Line

Investors are watching for further developments in the company's clinical pipeline. The next corporate updates will offer additional context on its financial trajectory.